UNSPSC 51342306: Lobucavir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C11H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U5PYQ1R2E, chemically known as 9-(2,3-bis-(hydroxymethyl)-1-cyclobutyl)guanine but generally known as lobucavir, which bears US NIH Compound Identifier 60786. European Medicines Agency schedules Lobucavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08544MIG.

UNSPSC 51342306 Lobucavir is a Commodity code for a specific antiviral pharmaceutical product; however, the recent state and local contract opportunities posted under this code do not align with lobucavir procurement. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, and Seminole County, Florida issued an IFB for Naloxone and Safe Drug Deactivation Systems. Neither solicitation involves lobucavir, suggesting either a classification mismatch in the state and local procurement systems or minimal recent demand for this specific therapeutic agent. State and local health departments and counties appear to be the issuing bodies tagging activity to this code, but the actual products being sourced—antibiotics and opioid-overdose emergency supplies—fall outside the lobucavir family.

The code shows little relevant recent activity tied to its nominal scope. The Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023) and the Illinois Department of Public Health antibiotic contract (awarded August 28, 2026, total contract value $2.99 million over three years) represent the only recent state and local opportunities surfaced under this code. Both are closed or completed awards, not open solicitations. Activity is concentrated in Florida and Illinois, with no indication of lobucavir procurement in the recent record.